A method includes receiving sensor data at a processor from sensors of an external medical device. The sensor data corresponds to at least a first body parameter value for a patient and a second body parameter value for the patient. The method includes determining a first depression-indicative value based on the first body parameter value, a second depression-indicative value based on the second body parameter value, a depression detection value as a function of a first weight applied to the first depression-indicative value and a second weight applied to the second depression-indicative value, and a depression state based at least in part on a comparison of the depression detection value to one or more threshold values.

The present application relates to a new stimulation design which can be utilized to treat neurological conditions. The stimulation system produces a burst mode stimulation which alters the neuronal activity of the predetermined site, thereby treating the neurological condition or disorder. The burst stimulus comprises a plurality of groups of spike pulses having a maximum inter-spike interval of 100 milliseconds. The burst stimulus is separated by a substantially quiescent period of time between the plurality of groups of spike pulses. This inter-group interval may comprise a minimum of 5 seconds.

Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve.

A system for differential recording connectable to an electrical lead with at least two electrodes, including:

the lead having a distal end;
at least one amplifier electrically connectable to the at least two electrodes, wherein the at least one amplifier subtracts a signal recorded by one of the at least two electrodes, from a signal recorded by the other one of the at least two electrodes to generate a differential signal;
a memory configured for storing said differential signal and reference indications of electrical signals associated with neural tissue;
a processing circuitry for detection of an anatomical position, wherein the processing circuitry calculates an anatomical position of the electrical lead based on processing of the differential signal and the reference indications of electrical signals associated with the neural tissue.

Methods for treating anxiety disorders and for reducing a risk associated with developing an anxiety disorder in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with anxiety disorders as well as an increased risk of developing an anxiety disorder. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to an anxiety disorder status in the patient. Other aspects are directed to reducing a likelihood of developing an anxiety disorder in patients presenting one or more anxiety disorder risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's anxiety disorder status or risk of developing an anxiety disorder. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve.

Provided are a method and device for neuro-stimulation. The method for neuro-stimulation includes: detecting a physiological activity signal of each brain region in at least one brain region of a patient through an implantable electrode device; comparing the detected physiological activity signal of the each brain region with a preset detection condition to determine whether the detected physiological activity signal of the each brain region belongs to an abnormal physiological activity signal; and controlling whether to apply an electrical stimulation signal to the at least one brain region through the implantable electrode device based on a determination result of the physiological activity signal of the each brain region.

Techniques are disclosed for delivering electrical stimulation therapy to a patient. In one example, a medical system delivers electrical stimulation therapy to a tissue of the patient via electrodes. The medical system determines a first response of a first sensed signal of the patient to the electrical stimulation therapy and a second response of a second sensed signal of the patient to the electrical stimulation therapy. Based on the first response and the second response for controlling the electrical stimulation therapy, the medical system selects one of the first sensed signal and the second sensed signal of the patient. The medical system adjusts a level of at least one parameter of the electrical stimulation therapy based on the selected one of the first sensed signal and the second sensed signal.

Methods for treating depression and for reducing a risk associated with developing depression in patients via therapeutic renal neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological conditions associated with depression as well as an increased risk of developing depression. One aspect of the present technology is directed to methods for improving a patient's calculated risk score corresponding to a depression status in the patient. Other aspects are directed to reducing a likelihood of developing depression in patients presenting one or more depression risk factors. Renal sympathetic nerve activity can be attenuated to improve a patient's depression status or risk of developing depression. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly configured to use, e.g., electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the renal sympathetic nerve.

Disclosed is a device for modulating a nerve of a patient by applying electrical stimulation to the nerve of the patient. The device includes a stimulation module that applies a signal to the nerve of the patient, and a controller that controls a signal to be applied to the stimulation module, wherein the signal to be applied to the stimulation module includes pulse bursts and a direct current (DC) waveform.

Devices and methods for manipulating devices such as micro-scale devices are provided. The devices can include a tether of various materials surrounded by a stiff body. The tether interfaces with microscale devices to draw them against the stiff body, holding the microscale devices in a locked position for insertion into or extraction out of tissue. The tensional hook and stiff body are configurable in a multitude of positions and geometries to provide increased engagement. Such configurations allow for a range of implantation and extraction surgical procedures for the device within research and clinical settings.